# Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR

> **NCT01744925** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib of routine dose
- **DRUG:** Icotinib of high dose

## Key facts

- **NCT ID:** NCT01744925
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-10
- **Primary completion:** 2017-11
- **Final completion:** 2017-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01744925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01744925, "Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01744925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*